Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Coronary Artery Disease (CAD) (Ischemic Heart Disease) drugs in development, 2024
The Coronary Artery Disease (CAD) (Ischemic Heart Disease) drugs in development market research report provides comprehensive information on the therapeutics...
Typhoid (bivalent) vaccine by Serum Institute of India for Typhoid Fever: Likelihood of Approval
Typhoid (bivalent) vaccine is under clinical development by Serum Institute of India and currently in Phase I for Typhoid Fever....
JNJ-8543 by Johnson & Johnson for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
JNJ-8543 is under clinical development by Johnson & Johnson and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According...
D3L-001 by D3 Bio for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
D3L-001 by D3 Bio for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to...
D3L-001 by D3 Bio for Gastric Cancer: Likelihood of Approval
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
Donepezil by Inventage Lab for Alzheimer's Disease: Likelihood of Approval
Donepezil is under clinical development by Inventage Lab and currently in Phase II for Alzheimer's Disease. According to GlobalData, Phase...
Bis-5 by L&L Biopharma for Endometrial Cancer: Likelihood of Approval
Bis-5 is under clinical development by L&L Biopharma and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...
Bis-5 by L&L Biopharma for Solid Tumor: Likelihood of Approval
Bis-5 is under clinical development by L&L Biopharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
IBI-363 by Innovent Biologics for Solid Tumor: Likelihood of Approval
IBI-363 is under clinical development by Innovent Biologics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
PRAX-628 by Praxis Precision Medicines for Epilepsy: Likelihood of Approval
PRAX-628 is under clinical development by Praxis Precision Medicines and currently in Phase II for Epilepsy. According to GlobalData, Phase...
LM-108 by LaNova Medicines for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
LM-108 is under clinical development by LaNova Medicines and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
SCG-101 by SCG Cell Therapy for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
SCG-101 is under clinical development by SCG Cell Therapy and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According...
MRT-2359 by Monte Rosa Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
MRT-2359 is under clinical development by Monte Rosa Therapeutics and currently in Phase II for Human Epidermal Growth Factor Receptor...
KYV-101 by Kyverna Therapeutics for Primary Progressive Multiple Sclerosis (PPMS): Likelihood of Approval
KYV-101 is under clinical development by Kyverna Therapeutics and currently in Phase II for Primary Progressive Multiple Sclerosis (PPMS). According...
KYV-101 by Kyverna Therapeutics for Secondary Progressive Multiple Sclerosis (SPMS): Likelihood of Approval
KYV-101 is under clinical development by Kyverna Therapeutics and currently in Phase II for Secondary Progressive Multiple Sclerosis (SPMS). According...
KYV-101 by Kyverna Therapeutics for Myasthenia Gravis: Likelihood of Approval
KYV-101 is under clinical development by Kyverna Therapeutics and currently in Phase II for Myasthenia Gravis. According to GlobalData, Phase...
Thiostrepton by RS Oncology for Non-Small Cell Lung Cancer: Likelihood of Approval
Thiostrepton is under clinical development by RS Oncology and currently in Phase II for Non-Small Cell Lung Cancer. According to...
BioGam by Microgen for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval
BioGam is under clinical development by Microgen and currently in Phase III for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). According...
Aflibercept biosimilar by Alvotech for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval
Aflibercept biosimilar is under clinical development by Alvotech and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration....